2420-2421 / 2953
Adjuvant HT plus RT versus RT in high-
risk PCa: 10-year results
•
Significant reduction in most 10-year endpoints
Trial
Treatment groups
Local
failure
(%)
Distant
metastases
(%)
DFS
(%)
OS
(%)
EORTC 22863
1,2
RT (n=208)
RT + goserelin for 36 months
[+ AA for 1 month] (n=207)
NR
NR
70
49
‡
23
48
‡
40
58
†
49
RTOG 85-31
3
RT (n=489)
RT + indefinite goserelin (n=488)
38
23
‡
39
24
†
23
a
37
‡a
39
49
**
RTOG 92-02
4,5
Goserelin + AA for 4 months
before and during RT, then:
- No further adjuvant HT (n=763)
- Goserelin for 24 months (n=758)
22
12
‡
23
15
‡
23
13
‡
52
54
a
No evidence of disease survival: survival in absence of locoregional failure/distant metastases
**P<0.01;
†
P<0.001;
‡
P<0.0001 vs RT alone
NR, not reported
DFS, disease-free survival
OS, overall survival
1. Bolla M, et al. Lancet 2002;360:103-8; 2. Bolla M, et al. Lancet Oncol
2010;11:1066-73; 3. Pilepich MV, et al. Int J Radiat Oncol Biol Phys
2005;61:1285-90; 4. Hanks GE, et al. JCO 2003;21:3972-8
5. Horwitz EM, et al. JCO 2008;26:2497-504